<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070979</url>
  </required_header>
  <id_info>
    <org_study_id>PR-03602.1</org_study_id>
    <nct_id>NCT01070979</nct_id>
  </id_info>
  <brief_title>Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.</brief_title>
  <official_title>A Multicenter, Double-Blind, Controlled, Randomized Study to Compare the Efficacy in Relief of Hot Flushes in Women Receiving Oral Estradiol Acetate Tablets, Oral Estradiol Tablets or Oral Conjugated Equine Estrogens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warner Chilcott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Warner Chilcott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, double-blind, controlled, parallel group, randomized study to compare the
      clinical benefit of Estradiol acetate tablets, estradiol tablets and conjugated equine
      estrogen tablets, each administered orally, once daily, to postmenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">September 2003</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 4, ITT (Intention to Treat) Population</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 12, ITT Population</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 4, ITT Population</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Patient self-reported outcome. Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep. Minimum 0/no hot flushes, Maximum 3/all severe hot flushes. Lower the score the greater the improvement in reducing hot flushes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 12, ITT Population</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Patient self-reported outcome. Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep. Minimum 0/no hot flushes, Maximum 3/all severe hot flushes. Lower the score the greater the improvement in reducing hot flushes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Urogenital Symptom Score, Week 4, ITT Population</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Urogenital Symptom Score, Week 8, ITT Population</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Urogenital Symptom Score, Week 12, ITT Population</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">249</enrollment>
  <condition>Hormone Replacement Therapy</condition>
  <arm_group>
    <arm_group_label>Estradiol acetate (E3A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conjugated equine estrogens (CEE):</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol acetate</intervention_name>
    <description>Tablet containing 0.9 mg E3A, daily oral administration.</description>
    <arm_group_label>Estradiol acetate (E3A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>Tablet containing 1 mg estradiol, daily oral administration.</description>
    <arm_group_label>Estradiol</arm_group_label>
    <other_name>Estrace</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conjugated equine estrogens</intervention_name>
    <description>Tablet containing 0.625 mg CEE, daily oral administration.</description>
    <arm_group_label>Conjugated equine estrogens (CEE):</arm_group_label>
    <other_name>Premarin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 40 years of age; bilateral oophorectomy ≥ 35 years of age.

          2. Non-hysterectomized women:

               -  Amenorrhea for ≥ 12 months or

               -  Amenorrhea for ≤ 12 months, but longer than 6 months, and serum FSH (follicle
                  stimulating hormone) levels &gt; 40 units/L and serum estradiol levels &lt; 20 pg /mL,

             Hysterectomized women:

               -  Bilateral oophorectomy - subjects may enter the study 6 weeks after surgery or

               -  History of removal of ovaries may be confirmed by - serum FSH levels &gt; 40 units/L
                  and serum estradiol levels &lt; 20 pg/mL or via surgical report / ultrasound.

          3. Seven or more moderate or severe hot flushes daily for 1 week or 60 or more moderate
             or severe flushes in 1 week during the 2 week screening period prior to study entry.

        Exclusion Criteria:

          1. Hormone therapy administered via the following routes and during the specified
             timeframes: oral within 8 weeks, vaginal (rings, creams, gels) within 1 week,
             transdermal within 4 weeks, intramuscular within 6 weeks, progestational implants,
             estrogen or estrogen/progestational injectable drug therapy within 3 months, estrogen
             pellet or progestational injectable within 6 months.

          2. Abnormal Pap smear suggestive of low grade squamous intraepithelial lesion (LGSIL) or
             worse. Enrollment of subjects with an ASCUS (atypical squamous cells of undetermined
             significance) interpretation must be discussed with the sponsor prior to
             randomization.

          3. Urinary tract infection

          4. Congestive heart failure

          5. Uncontrolled hypertension; sitting systolic BP ≥ 160 mmHg or diastolic ≥ 95 mmHg

          6. History of stroke or transient ischemic attacks

          7. Treatment with anticoagulants (heparin or warfarin).

          8. Uncontrolled thyroid disorders.

          9. Insulin-dependent diabetes mellitus.

         10. Increase frequency or severity of headaches including migraines during previous
             estrogen therapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herman Ellman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Warner Chilcott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Longwood</city>
        <state>Florida</state>
        <zip>32779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Palm Springs</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34285</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Laurel</city>
        <state>Maryland</state>
        <zip>20707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Mogadore</city>
        <state>Ohio</state>
        <zip>44260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <results_first_submitted>February 14, 2011</results_first_submitted>
  <results_first_submitted_qc>March 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 8, 2011</results_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment of postmenopausal women for relief of hot flushes and urogenital symptoms beginning Feb '03 at 33 sites in the US.</recruitment_details>
      <pre_assignment_details>Discontinue estrogen/hormone therapy prior to enrollment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Estradiol Acetate (E3A)</title>
          <description>1 tablet daily containing 0.9 mg estradiol acetate</description>
        </group>
        <group group_id="P2">
          <title>Estradiol</title>
          <description>1 tablet daily containing 1 mg estradiol</description>
        </group>
        <group group_id="P3">
          <title>Conjugated Equine Estrogens (CEE)</title>
          <description>1 tablet daily containing 0.625 mg conjugated equine estrogen</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery, moving, personal, abn. labs</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No study drug taken</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Estradiol Acetate (E3A)</title>
          <description>1 tablet daily containing 0.9 mg estradiol acetate</description>
        </group>
        <group group_id="B2">
          <title>Estradiol</title>
          <description>1 tablet daily containing 1 mg estradiol</description>
        </group>
        <group group_id="B3">
          <title>Conjugated Equine Estrogens (CEE)</title>
          <description>1 tablet daily containing 0.625 mg conjugated equine estrogen</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="85"/>
            <count group_id="B4" value="249"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.2" spread="6.6"/>
                    <measurement group_id="B2" value="52.3" spread="7.0"/>
                    <measurement group_id="B3" value="53.8" spread="6.3"/>
                    <measurement group_id="B4" value="52.8" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 4, ITT (Intention to Treat) Population</title>
        <description>Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Intention to Treat (ITT) with Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Estradiol Acetate (E3A)</title>
            <description>1 tablet daily containing 0.9 mg estradiol acetate</description>
          </group>
          <group group_id="O2">
            <title>Estradiol</title>
            <description>1 tablet daily containing 1 mg estradiol</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Equine Estrogens (CEE)</title>
            <description>1 tablet daily containing 0.625 mg conjugated equine estrogen</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 4, ITT (Intention to Treat) Population</title>
          <description>Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep</description>
          <population>Intention to Treat (ITT) with Last Observation Carried Forward (LOCF)</population>
          <units>Change in Hot Flush Count</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.1" spread="4.5"/>
                    <measurement group_id="O2" value="-62.0" spread="4.5" lower_limit="0.721" upper_limit="1.048"/>
                    <measurement group_id="O3" value="-54.5" spread="4.3" lower_limit="0.833" upper_limit="1.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 4, ITT Population</title>
        <description>Patient self-reported outcome. Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep. Minimum 0/no hot flushes, Maximum 3/all severe hot flushes. Lower the score the greater the improvement in reducing hot flushes.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Intention to Treat (ITT) with Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Estradiol Acetate (E3A)</title>
            <description>1 tablet daily containing 0.9 mg estradiol acetate</description>
          </group>
          <group group_id="O2">
            <title>Estradiol</title>
            <description>1 tablet daily containing 1 mg estradiol</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Equine Estrogens (CEE)</title>
            <description>1 tablet daily containing 0.625 mg conjugated equine estrogen</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 4, ITT Population</title>
          <description>Patient self-reported outcome. Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep. Minimum 0/no hot flushes, Maximum 3/all severe hot flushes. Lower the score the greater the improvement in reducing hot flushes.</description>
          <population>Intention to Treat (ITT) with Last Observation Carried Forward (LOCF)</population>
          <units>Change in Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.106"/>
                    <measurement group_id="O2" value="-0.51" spread="0.106"/>
                    <measurement group_id="O3" value="-0.59" spread="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 12, ITT Population</title>
        <description>Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Intention to Treat (ITT) with Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Estradiol Acetate (E3A)</title>
            <description>1 tablet daily containing 0.9 mg estradiol acetate</description>
          </group>
          <group group_id="O2">
            <title>Estradiol</title>
            <description>1 tablet daily containing 1 mg estradiol</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Equine Estrogens (CEE)</title>
            <description>1 tablet daily containing 0.625 mg conjugated equine estrogen</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 12, ITT Population</title>
          <description>Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep</description>
          <population>Intention to Treat (ITT) with Last Observation Carried Forward (LOCF)</population>
          <units>Change in Hot Flush Count</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.6" spread="4.8"/>
                    <measurement group_id="O2" value="-72.2" spread="4.7"/>
                    <measurement group_id="O3" value="-67.2" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 12, ITT Population</title>
        <description>Patient self-reported outcome. Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep. Minimum 0/no hot flushes, Maximum 3/all severe hot flushes. Lower the score the greater the improvement in reducing hot flushes.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Intention to Treat (ITT) with Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Estradiol Acetate (E3A)</title>
            <description>1 tablet daily containing 0.9 mg estradiol acetate</description>
          </group>
          <group group_id="O2">
            <title>Estradiol</title>
            <description>1 tablet daily containing 1 mg estradiol</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Equine Estrogens (CEE)</title>
            <description>1 tablet daily containing 0.625 mg conjugated equine estrogen</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 12, ITT Population</title>
          <description>Patient self-reported outcome. Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep. Minimum 0/no hot flushes, Maximum 3/all severe hot flushes. Lower the score the greater the improvement in reducing hot flushes.</description>
          <population>Intention to Treat (ITT) with Last Observation Carried Forward (LOCF)</population>
          <units>Change in Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="0.127"/>
                    <measurement group_id="O2" value="-1.34" spread="0.125"/>
                    <measurement group_id="O3" value="-1.17" spread="0.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Urogenital Symptom Score, Week 4, ITT Population</title>
        <description>Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Intention to Treat (ITT) with Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Estradiol Acetate (E3A)</title>
            <description>1 tablet daily containing 0.9 mg estradiol acetate</description>
          </group>
          <group group_id="O2">
            <title>Estradiol</title>
            <description>1 tablet daily containing 1 mg estradiol</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Equine Estrogens (CEE)</title>
            <description>1 tablet daily containing 0.625 mg conjugated equine estrogen</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Urogenital Symptom Score, Week 4, ITT Population</title>
          <description>Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.</description>
          <population>Intention to Treat (ITT) with Last Observation Carried Forward (LOCF)</population>
          <units>Change in Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.89" spread="0.413"/>
                    <measurement group_id="O2" value="-2.26" spread="0.407"/>
                    <measurement group_id="O3" value="-1.96" spread="0.398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Urogenital Symptom Score, Week 8, ITT Population</title>
        <description>Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Intention to Treat (ITT) with Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Estradiol Acetate (E3A)</title>
            <description>1 tablet daily containing 0.9 mg estradiol acetate</description>
          </group>
          <group group_id="O2">
            <title>Estradiol</title>
            <description>1 tablet daily containing 1 mg estradiol</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Equine Estrogens (CEE)</title>
            <description>1 tablet daily containing 0.625 mg conjugated equine estrogen</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Urogenital Symptom Score, Week 8, ITT Population</title>
          <description>Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.</description>
          <population>Intention to Treat (ITT) with Last Observation Carried Forward (LOCF)</population>
          <units>Change in Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="0.432"/>
                    <measurement group_id="O2" value="-2.58" spread="0.425"/>
                    <measurement group_id="O3" value="-2.42" spread="0.416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Urogenital Symptom Score, Week 12, ITT Population</title>
        <description>Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Intention to Treat (ITT) with Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Estradiol Acetate (E3A)</title>
            <description>1 tablet daily containing 0.9 mg estradiol acetate</description>
          </group>
          <group group_id="O2">
            <title>Estradiol</title>
            <description>1 tablet daily containing 1 mg estradiol</description>
          </group>
          <group group_id="O3">
            <title>Conjugated Equine Estrogens (CEE)</title>
            <description>1 tablet daily containing 0.625 mg conjugated equine estrogen</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Urogenital Symptom Score, Week 12, ITT Population</title>
          <description>Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.</description>
          <population>Intention to Treat (ITT) with Last Observation Carried Forward (LOCF)</population>
          <units>Change in Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.49" spread="0.437"/>
                    <measurement group_id="O2" value="-2.59" spread="0.431"/>
                    <measurement group_id="O3" value="-2.52" spread="0.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 months</time_frame>
      <desc>February 2003 thru September 2003, One subject randomized to estradiol group never took any study drug therefore not included in AE assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Estradiol Acetate (E3A)</title>
          <description>1 tablet daily containing 0.9 mg estradiol acetate</description>
        </group>
        <group group_id="E2">
          <title>Estradiol</title>
          <description>1 tablet daily containing 1 mg estradiol</description>
        </group>
        <group group_id="E3">
          <title>Conjugated Equine Estrogens (CEE)</title>
          <description>1 tablet daily containing 0.625 mg conjugated equine estrogen</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (6.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (6.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Abdominal Distention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vaginosis Fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Grexan Wulff, Manager Regulatory Affairs</name_or_title>
      <organization>Warner Chilcott</organization>
      <phone>973-442-3376</phone>
      <email>gwulff@wcrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

